We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lilly, Alkermes, Amylin Submit Response to FDA on Bydureon
Lilly, Alkermes, Amylin Submit Response to FDA on Bydureon
April 23, 2010
Eli Lilly, Alkermes and Amylin Pharmaceuticals have replied to an FDA action letter on their NDA for once-weekly diabetes drug Bydureon.